1.26

4.14% 0.06

Prelude Therapeutics Inc (PRLD)

Overview News Price History Option Chain Financials Discussions Forecast

Prelude Therapeutics Inc stock is traded at $1.26, with a volume of 233.13K. It is up +4.14% in the last 24 hours and down -37.52% over the past month. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Previous Close:

$1.20

Open:

$1.21

24h Volume:

233.13K

Relative Volume:

0.71

Market Cap:

$67.96M

Revenue:

Net Income/Loss:

$-121.83M

P/E Ratio:

-0.5806

EPS:

-2.17

Net Cash Flow:

$-110.58M

1W Performance:

-12.61%

1M Performance:

-37.52%

6M Performance:

-67.62%

1Y Performance:

-44.95%

1-Day Range:

$1.18

$1.32

1-Week Range:

$1.10

$1.4198

52-Week Range:

$1.10

$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name

Prelude Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(302) 467-1280

Address

175 INNOVATION BOULEVARD, WILMINGTON

Employee

128

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

PRLD's Discussions on Twitter

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-29-22	Initiated	Jefferies	Buy
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy
Apr-26-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Barclays	Overweight
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Goldman	Neutral
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight

View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

Oct 31, 2024

PRLD stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia

Oct 31, 2024

Prelude Therapeutics’ (PRLD) Buy Rating Reiterated at HC Wainwright - Defense World

Oct 31, 2024

Oct 30, 2024

PRLD stock touches 52-week low at $1.32 amid market challenges By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 29, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts - Investing.com Nigeria

Oct 29, 2024

Oct 28, 2024

Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal data readouts By Investing.com - Investing.com South Africa

Oct 28, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 28, 2024

Oct 27, 2024

Prelude Therapeutics price target lowered to $1 from $3 at Barclays - Yahoo Finance

Oct 27, 2024

Oct 26, 2024

Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium - MyChesCo

Oct 26, 2024

Oct 24, 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance

Oct 24, 2024

PRLD stock touches 52-week low at $1.65 amid market challenges - Investing.com India

Oct 24, 2024

Oct 23, 2024

PRLD stock touches 52-week low at $1.65 amid market challenges By Investing.com - Investing.com South Africa

Oct 23, 2024

Oct 16, 2024

Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip

Oct 16, 2024

Oct 13, 2024

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Sees Significant Decline in Short Interest - MarketBeat

Oct 13, 2024

Oct 11, 2024

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MyChesCo

Oct 11, 2024

Oct 10, 2024

Prelude Therapeutics Showcases Innovative SMARCA Degrader Programs at Barcelona Symposium - MyChesCo

Oct 10, 2024

Oct 09, 2024

Prelude Therapeutics shares updates on cancer drug trials By Investing.com - Investing.com Canada

Oct 09, 2024

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium - Yahoo Finance

Oct 09, 2024

Oct 04, 2024

Wall Street today: US stocks trade higher as investors re-evaluate big Fed rate cut potential, Intel Corp. gains 1.83% - MSN

Oct 04, 2024

Sep 29, 2024

Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Increases By 37.0% - MarketBeat

Sep 29, 2024

Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World

Sep 29, 2024

RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World

Sep 29, 2024

Squarepoint Ops LLC Grows Stock Holdings in Teleflex Incorporated (NYSE:TFX) - Defense World

Sep 29, 2024

Axa S.A. Acquires 1,964 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World

Sep 29, 2024

Sep 28, 2024

Employees Retirement System of Texas Makes New Investment in Nova Ltd. (NASDAQ:NVMI) - Defense World

Sep 28, 2024

Sep 23, 2024

FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo

Sep 23, 2024

19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute

Sep 20, 2024

First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7

Sep 20, 2024

Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat

Sep 20, 2024

Sep 19, 2024

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo

Sep 19, 2024

Sep 18, 2024

Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online

Sep 18, 2024

Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News

Sep 18, 2024

Sep 17, 2024